Agios Pharma (AGIO) Tops Q4 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. KNX
10. QGEN

Go back to Agios Pharma (AGIO) Tops Q4 EPS by 12c

Agios Reports Fourth Quarter and Full Year 2019 Financial Results

February 13, 2020 7:00 AM EST

Fourth Quarter TIBSOVO® Net Revenue of $19.6M and $59.9M for Full Year 2019; Full Year 2020 U.S. TIBSOVO® Net Revenue Expected to be Between $105-115 Million

New Clinical Data from Mitapivat in Thalassemia and Sickle Cell Disease to be Submitted for Presentation at the European Hematology Association Annual Congress in June

Investigational New Drug Submission for AG-946, a Next Generation PKR Activator, Expected in Q1

CAMBRIDGE, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today reported business highlights and financial results for the fourth quarter and... More